Now showing items 1-4 of 4

    • Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease 

      Petzer, Jacobus; Castagnoli, Neal; Schwarzschild, Michael A.; Chen, Jiang-Fan; Van der Schyf, J. (Springer, 2009)
      Inadequacies of the current pharmacotherapies to treat Parkinson’s disease (PD) have prompted efforts to identify novel drug targets. The adenosine A2A receptor is one such target. Antagonists of this receptor (A2A ...
    • Dual-Target-Directed Drugs that Block Monoamne Oxidase B and Adenosine A2A Receptors for Parkiinson's Disease 

      Petzer, Jacobus; Castagnoli, Neal; Schwarzschild, Michael A; Chen,Jiang -Fan; Van der Schyf, Cornelis J (Springer, 2009)
      Inadequacies of the current pharmacotherapies to treat Parkinson's disease (PD) have prompted efforts to identify novel drug targets. The adenosine A2A receptor is one such target. Antagonists of this receptor (A2A ...
    • Inhibition of monoamine oxidase B by N-methyl-2-phenylmaleimides 

      Manley-king, Clarina Ilara; Terre'blanche, Gisella; Bergh, Jacobus; Petzer, Jacobus; Castagnoli, Neal Jr (Elsevier Ltd, 2009)
      Based on a recent report that 1-methyl-3-phenylpyrrolyl analogues are moderately potent reversible inhibitors of the enzyme monoamine oxidase B (MAO-B), a series of structurally related N-methyl-2-phenylmaleimidyl analogues ...
    • Inhibition of monoamine oxidase by E_-styrylisatin analogues 

      Van Der Walt, Elizna Magdalena; Bergh, Jacobus; Petzer, Jacobus; Malan, Sarel; Castagnoli, N Jr; Milczek, E M; Edmondsonb, Dale E (Elsevier Ltd, 2009)
      Previous studies have shown that (E)-8-(3-chlorostyryl)caffeine (CSC) is a specific reversible inhibitor of human monoamine oxidase B (MAO-B) and does not bind to human MAO-A. Since the small molecule isatin is a natural ...